Lifecore Biomedical, Inc. De (LFCR) EBITDA (2010 - 2025)

Lifecore Biomedical's EBITDA history runs 16 years deep, the most recent figure standing at $5.3 million for Q2 2025.

• In Q2 2025, EBITDA rose 147.88% year-over-year to $5.3 million; the TTM figure through May 2025 stood at -$17.2 million (down 181.17% YoY), while the FY2025 annual figure was -$17.2 million, down 94.99% from the prior year.
• EBITDA was $5.3 million for Q2 2025 at Lifecore Biomedical, up from -$9.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $15.6 million in Q1 2024 to a low of -$38.3 million in Q4 2021.
• Historically, EBITDA has averaged -$7.6 million across 5 years, with a median of -$7.8 million in 2023.
• The sharpest annual moves came in 2021 and 2023: EBITDA plunged 1377.28% in 2021, then surged 213.56% in 2023.
• A 5-year view of EBITDA shows it stood at -$38.3 million in 2021, then soared by 67.28% to -$12.5 million in 2022, then soared by 213.56% to $14.2 million in 2023, then plunged by 113.78% to -$2.0 million in 2024, then surged by 371.92% to $5.3 million in 2025.
• The last three EBITDA figures came in at $5.3 million (Q2 2025), -$9.0 million (Q1 2025), and -$2.0 million (Q4 2024), per Business Quant data.